ReNeuron Group Plc (RENE) - Financial and Strategic SWOT Analysis Review

ReNeuron Group Plc (RENE) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

ReNeuron Group Plc (ReNeuron) is a stem cell company that develops innovative stem cell therapies targeting areas of significant unmet medical need. The company’s therapeutic candidates in clinical development are focused at treating patients left disabled by a stroke and the blindness-causing disease, retinitis pigmentosa, oncology, diabetes and neurodegenerative diseases. It utilizes exclusive stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be administered off-the-shelf to any fit patient without the requirement for additional immunosuppressive drug treatments. ReNeuron’s technology platforms include hRPC platform; CTX platform and Exosomes platform. ReNeuron ReNeuron is headquartered in Pencoed, Bridgend, the UK.

ReNeuron Group Plc Key Recent Developments

Aug 12,2020: ReNeuron Group : Changes to non-executive Board
Jul 20,2020: ReNeuron Group : Preliminary results for the year ended 31 March 2020
Jun 25,2020: ReNeuron signs new exosome research collaboration
Jun 17,2020: ReNeuron provides program and regulatory approvals update
Apr 07,2020: ReNeuron announces exosome research collaboration

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
ReNeuron Group Plc - Key Facts
ReNeuron Group Plc - Key Employees
ReNeuron Group Plc - Key Employee Biographies
ReNeuron Group Plc - Major Products and Services
ReNeuron Group Plc - History
ReNeuron Group Plc - Company Statement
ReNeuron Group Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
ReNeuron Group Plc - Business Description
Business Segment: License Fee
Performance
Business Segment: Royalty
Performance
ReNeuron Group Plc - Corporate Strategy
ReNeuron Group Plc - SWOT Analysis
SWOT Analysis - Overview
ReNeuron Group Plc - Strengths
ReNeuron Group Plc - Weaknesses
ReNeuron Group Plc - Opportunities
ReNeuron Group Plc - Threats
ReNeuron Group Plc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
ReNeuron Group Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 12, 2020: ReNeuron Group : Changes to non-executive Board
Jul 20, 2020: ReNeuron Group : Preliminary results for the year ended 31 March 2020
Jun 25, 2020: ReNeuron signs new exosome research collaboration
Jun 17, 2020: ReNeuron provides program and regulatory approvals update
Apr 07, 2020: ReNeuron announces exosome research collaboration
Apr 06, 2020: ReNeuron Update Regarding COVID-19
Apr 03, 2020: ReNeuron Group: COVID-19 update
Aug 21, 2019: ReNeuron Group: Appointments to scientific advisory board
Aug 14, 2019: Grant-funded collaboration with exosome platform
Jul 16, 2019: ReNeuron Group: Key patent grants expand exosome IP portfolio
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
ReNeuron Group Plc, Key Facts
ReNeuron Group Plc, Key Employees
ReNeuron Group Plc, Key Employee Biographies
ReNeuron Group Plc, Major Products and Services
ReNeuron Group Plc, History
ReNeuron Group Plc, Subsidiaries
ReNeuron Group Plc, Key Competitors
ReNeuron Group Plc, Ratios based on current share price
ReNeuron Group Plc, Annual Ratios
ReNeuron Group Plc, Annual Ratios (Cont...1)
ReNeuron Group Plc, Interim Ratios
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
ReNeuron Group Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
ReNeuron Group Plc, Performance Chart (2016 - 2020)
ReNeuron Group Plc, Ratio Charts
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook